/
LTRN
$4.07+$0.21 (+5.44%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$49.3M
13M shares
52-week range
$1.11 – $5.74
64% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
5.97%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-10.34
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | −$2.5K | $1.6K | $0 | $0 | $0 | $174.8K | $0 | $0 |
| Gross profit | $2.5K | −$1.6K | $0 | $0 | $0 | −$174.8K | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $572.1K | $953.2K | $2.2M | $7.6M | $8.6M | $11.9M | $16.1M | $11.5M |
| Operating income | −$1.7M | −$2.4M | −$5.9M | −$12.6M | −$14.4M | −$17.9M | −$22.2M | −$18.0M |
| EBITDA | −$1.7M | −$2.4M | −$5.9M | −$12.4M | −$14.0M | −$15.8M | −$20.8M | −$17.1M |
| Net income | −$1.7M | −$2.4M | −$5.9M | −$12.4M | −$14.3M | −$16.0M | −$20.8M | −$17.1M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -0.28 | -0.39 | -0.95 | -1.13 | -1.31 | -1.47 | -1930.92 | -1.57 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2M | $-1.51 | $-1.51–$-1.51 | 1 |
| 2027 | $15M | $-2.02 | $-2.02–$-2.02 | 1 |
| 2028 | $34M | $-2.11 | $-2.11–$-2.11 | 1 |
| 2029 | $0 | $-2.20 | $-2.20–$-2.20 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Lantern Pharma Inc. Common Stock
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.
www.lanternpharma.com- Employees
- 16
- IPO / List date
- Jun 11, 2020
- HQ
- DALLAS, TX
Held by traders on TradeandTell
No one on the platform currently holds LTRN.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 116,000 | $158.9K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded LTRN yet.
